f***!!! intercytex is collapsing!

MacAttack

Established Member
Reaction score
0
guys...that stock keeps f*****g going lower and lower...setting new lows...its like a f*****g hooker! its less then 1/2 the value now when hair cloning was supposed 2 make it huge.
 

Optimist

Established Member
Reaction score
1
Re: f***!!! intercytex is collapsing!

MacAttack said:
guys...that stock keeps f****ing going lower and lower...setting new lows...its like a f****ing hooker! its less then 1/2 the value now when hair cloning was supposed 2 make it huge.

Who cares? They have no revenue, what do you expect the stock to do, skyrocket?

Since when does a low stock mean a company is collapsing? What we should be looking at his how its new product Valveta (I think that is how it is spelled) does. They are suppose to launch it this year. It is unrelated to hairloss, but will be telling about the abilities of the company.
 

elguapo

Experienced Member
Reaction score
0
I for one would like to see Aderans or other carry the HM torch, rather than Intercytex. First of all, they already have the cash to carry HM through, do they not? Also, they would probably be less likely to release HM if the technology is not reliable, due to the lesson that they (hopefully) learned with their early "plugs" and the rap they got from that, whereas Intercytex might be a little more desparate for the money. Also, they wouldn't be in a rush to release the product too early for the same reason, whereas Aderans has money already.

But that's not how it is, so I'm still routing for Intercytex. The other side of the coin is that they know their stock is low, which hopefully makes them HUNGRY to get HM working properly. I guess it all depends on how you look at it.
 

hairwegoagain

Senior Member
Reaction score
6
Re: f***!!! intercytex is collapsing!

guys...that stock keeps f****ing going lower and lower...setting new lows...its like a f****ing hooker! its less then 1/2 the value now when hair cloning was supposed 2 make it huge.

Seconded. Who cares? Hopefully you didn't bet the farm - this is a highly speculative equity...but remember, you don't lose (or make) $ until you sell.

Optimist said:
Who cares? They have no revenue, what do you expect the stock to do, skyrocket?

Precisely. They do not have a product. They are consuming funds through operation just like all startup companies do...in the hopes that someday a profitable business will be born. Maybe it will, maybe it won't...the uncertainty is reflected in its price.
 

latecomer

Established Member
Reaction score
0
http://www.sharecrazy.com/share2607shar ... x5680t.htm

The share price is bound to go down due to their 2006 posted results. Don't forget that many of the companies loss are due to the fact that a lot is still part of R&D and they don't have a product out there to make them any money yet. Once the clinical trials come to an end and they start releasing their products the value of the shares will rocket! But hold off from buying them yet as I think the price will drop a bit further but once it reaches a low make sure you buy as if the phase 2 results of HM is positive you are bound to make a bit of cash to help pay for future proceedures!
 

hairwegoagain

Senior Member
Reaction score
6
latecomer said:
if the phase 2 results of HM is positive you are bound to make a bit of cash to help pay for future proceedures!

Operative word = "if"

If they're negative, one would stand to lose a lot if not all of his investment. If they're neutral then the stock could languish indefinitely.

If you're a gambler that likes playing the red or black and can afford to lose 100% of your investment, go for it! Might pay off. If not, avoid this pink sheet stock.
 

cubeall

New Member
Reaction score
0
Financially the company looks pretty sound. During this last year they have actually expanded the company which is indicated by the increase in fixed assets. There is also a pretty good stream of income from investment interest that is offsetting some of the losses that are being posted. All in all it looks like they are pretty well funded in general.

The accounting standards in Europe are different than they are here in the US. In the US any R&D is expensed on the income statement and there is no related asset that is increased. In Europe the R&D expenses are capitalized into an asset. This could possibly be responsible for the huge increase in assets which makes it a bit harder to interpret because there is not really an asset yet even though it is represented in the Financial Statements.
 

Optimist

Established Member
Reaction score
1
Sirius satelite radio started out at $60 and is now at $3 and they have a great product. I'm not sure how a declining stock price affects research, but I guess you alarmists know something I don't.
 

cubeall

New Member
Reaction score
0
It's tough to compare Sirius or XM's situation with Intercytex or any other company in general especially in the medical industry. Even though Sirius has a good product it has experienced a decline in profitability for several reasons, mostly from increasing competition from the iPod. Another large factor influencing the losses is that Sirius and XM were required to agree to never merge with each other. Because of the nature of the industry, having two companies that provide the exact same service has had the effect of only cannibalizing a small subsection of the population instead of creating new customers.

Stock prices can be a good indicator of a companies wellbeing. Sirius' stock, as you pointed out, has dropped and has stayed down for a while now and coincidentally they are on the verge of bankruptcy. As I've said before, comparing this with Intercytex doesn't make sense because the industries are completely different.
 

Optimist

Established Member
Reaction score
1
cubeall said:
It's tough to compare Sirius or XM's situation with Intercytex or any other company in general especially in the medical industry. Even though Sirius has a good product it has experienced a decline in profitability for several reasons, mostly from increasing competition from the iPod. Another large factor influencing the losses is that Sirius and XM were required to agree to never merge with each other. Because of the nature of the industry, having two companies that provide the exact same service has had the effect of only cannibalizing a small subsection of the population instead of creating new customers.

Stock prices can be a good indicator of a companies wellbeing. Sirius' stock, as you pointed out, has dropped and has stayed down for a while now and coincidentally they are on the verge of bankruptcy. As I've said before, comparing this with Intercytex doesn't make sense because the industries are completely different.


Actually the comparison makes fine sense, although I really hate to get caught up on it. None of your points demonstrate that a declining stock means a product will fail. As both Sirius and XM stocks have declined, their product has gotten better and it will not be going anywhere. Do you think Satelite radio is going to dissapear because of their declining stock? If you answer yes, then you have reason to fear that HM will fail as well and I have reason to think you know little about business.
 

cubeall

New Member
Reaction score
0
To cut straight to the point, the appropriate question is not whether satellite radio will be around because of declining stock. Most likely it will be around even if Sirius fails. What would make more sense to ask would be if the drop in stock price is an indicator of Sirius' going concern as a company. Since Sirius' failure to make adequate profits has actually caused the stock to drop then in this case it is a pretty good indicator of the success of the company. Additionally it is no secret that Sirius is in great financial difficulty right now. They have been pretty transparent with the public about that which is the main reason they are pushing so hard for a merger with XM.

What I was saying in the previous post is that you can't compare Sirius with Intercytex because the nature of the industry is far too different. Losses in the medical industry are acceptable during the research phase because they are creating a product. The losses are capitalized which results into an asset on the balance sheet. Sirius' only initial startup expense was what was spent to launch the satellites which cost them tens of millions of dollars. They have continued to attempt to post profits but have been unable to do so.

For these reasons interpreting the stock or Financials of these companies in the same way will give you inaccurate conclusions if you don't consider the nature of the industry. Simply put, you can't just look at one number for everything and believe it will always give you the right answer.
 

latecomer

Established Member
Reaction score
0
What you guys also need to take into account is that HM is not the only thing intercytex is concentrating on. Many of the other products that they are researching are also pretty good and will help the medical industry.
 

Optimist

Established Member
Reaction score
1
cubeall said:
To cut straight to the point, the appropriate question is not whether satellite radio will be around because of declining stock. Most likely it will be around even if Sirius fails. What would make more sense to ask would be if the drop in stock price is an indicator of Sirius' going concern as a company. Since Sirius' failure to make adequate profits has actually caused the stock to drop then in this case it is a pretty good indicator of the success of the company. Additionally it is no secret that Sirius is in great financial difficulty right now. They have been pretty transparent with the public about that which is the main reason they are pushing so hard for a merger with XM.

What I was saying in the previous post is that you can't compare Sirius with Intercytex because the nature of the industry is far too different. Losses in the medical industry are acceptable during the research phase because they are creating a product. The losses are capitalized which results into an asset on the balance sheet. Sirius' only initial startup expense was what was spent to launch the satellites which cost them tens of millions of dollars. They have continued to attempt to post profits but have been unable to do so.

For these reasons interpreting the stock or Financials of these companies in the same way will give you inaccurate conclusions if you don't consider the nature of the industry. Simply put, you can't just look at one number for everything and believe it will always give you the right answer.

I am not going to digress into an argument about my analogy. I not saying the companies are the same. I am only saying that Sirius stock fell by 3000% and they have a great product and to say that HM is not going to happen because Intercytex stock fell by 50% is foolish. If you want to get technical and the differences and similiarities, nock yourself out, personally, I think the differences between the two supports the argument that the fallign stock price is not going to hurt HM.
 

cubeall

New Member
Reaction score
0
You're right. That's exactly what these differences support. The financial statements indicate that they seem to have plenty of funding, enough to support their continual research expense.

Although Sirius' stock has plummeted and they are not doing well as a company, Intercytex does not seem to be following the same trend i.e. their drop in stock price does not mean they are failing financially.
 

Optimist

Established Member
Reaction score
1
cubeall said:
You're right. That's exactly what these differences support. The financial statements indicate that they seem to have plenty of funding, enough to support their continual research expense.

Although Sirius' stock has plummeted and they are not doing well as a company, Intercytex does not seem to be following the same trend i.e. their drop in stock price does not mean they are failing financially.

Ahh, all that argumentation and we ended up agreeing? :)
 

elguapo

Experienced Member
Reaction score
0
Since we have a couple of market-savvy members on this board, and we are on the topic, answer me this...

What happens if Intercytex does not release data or give some sort of status on their TRC Phase II study by this summer, or at latest this fall? Will their stock go down even further in that case? Or don't investors (or whoever's decisions or actions influence the price of their stock) pay attention to when they said they would have something to say, and hold them to it?
 

Optimist

Established Member
Reaction score
1
elguapo said:
Since we have a couple of market-savvy members on this board, and we are on the topic, answer me this...

What happens if Intercytex does not release data or give some sort of status on their TRC Phase II study by this summer, or at latest this fall? Will their stock go down even further in that case? Or don't investors (or whoever's decisions or actions influence the price of their stock) pay attention to when they said they would have something to say, and hold them to it?

As a rule, failure to meet deadlines and projections is bad for stocks. Savvy CEOS usually lowball projections so that they can beat their expectations which usually gives the stock a spike. Intercytex is definately a company that aims high and hits low.
 

cubeall

New Member
Reaction score
0
What happens if Intercytex does not release data or give some sort of status on their TRC Phase II study by this summer, or at latest this fall?

According to this link: http://www.baldingblog.com/2006/11/08/i ... -i-trials/
phase II trials are expected to complete by the end of 2008. Although I noticed Optimist's post indicating that it would more likely be 2007.

Optimist, where did you find the conflicting information about the ending date of the Phase II trials?
 

Optimist

Established Member
Reaction score
1
cubeall said:
What happens if Intercytex does not release data or give some sort of status on their TRC Phase II study by this summer, or at latest this fall?

According to this link: http://www.baldingblog.com/2006/11/08/i ... -i-trials/
phase II trials are expected to complete by the end of 2008. Although I noticed Optimist's post indicating that it would more likely be 2007.

Optimist, where did you find the conflicting information about the ending date of the Phase II trials?

Cubeall,

I don't recall saying that they would end in 2007, if I did it was my mistake. According to Intercytex, preliminary data will be available in the 1st half of 2007, I have said that and that may be the cause for the mixup.
 

cubeall

New Member
Reaction score
0
oh, ok. I noticed a post on that link by someone named Optimist saying,

I believe intercytex says the Phase II trials will be done by the end of 2007. They started several months ago and are expected to last 12 months.

and I assumed it was you. I wanted to follow that up and see if there was more information you found. It's possible whoever posted that mixed the data up and was referring to trials other than HM.
 
Top